{"id":89328,"date":"2023-10-26T12:05:57","date_gmt":"2023-10-26T10:05:57","guid":{"rendered":"https:\/\/www.pcb.ub.edu\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/"},"modified":"2025-10-13T15:24:44","modified_gmt":"2025-10-13T13:24:44","slug":"idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2","status":"publish","type":"post","link":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/","title":{"rendered":"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2"},"content":{"rendered":"<p><strong><a href=\"https:\/\/www.pcb.ub.edu\/es\/empresa\/idp-discovery-pharma\/\" target=\"_blank\" rel=\"noopener\">IDP Pharma<\/a>, una empresa de biotecnolog\u00eda en fase cl\u00ednica pionera en el desarrollo de f\u00e1rmacos que bloquean y degradan directamente a las prote\u00ednas intr\u00ednsecamente desordenadas (IDPs, del ingl\u00e9s <em>intrinsically disordered proteins<\/em>), ha anunciado hoy que se ha administrado su f\u00e1rmaco experimental IDP-121 con \u00e9xito al primer paciente en el ensayo IDP-121-001 CASSANDRA, un estudio multic\u00e9ntrico, abierto de fase I\/II para el tratamiento de neoplasias malignas hematol\u00f3gicas dependientes de cMyc.<\/strong><\/p>\n<p>El oncog\u00e9n cMyc se activa en la mayor\u00eda de los c\u00e1nceres mediante mecanismos gen\u00e9ticos, epigen\u00e9ticos y\/o postraduccionales, estando la funci\u00f3n de cMyc alterada en aproximadamente el 70% de los tumores. La conexi\u00f3n entre la prote\u00edna cMyc y el inicio y progresi\u00f3n del c\u00e1ncer resalta la posible importancia terap\u00e9utica de su inhibici\u00f3n. IDP-121 est\u00e1 dise\u00f1ado para bloquear la funci\u00f3n de la prote\u00edna cMyc y degradarla selectivamente.<\/p>\n<p>\u201cIDP-121 ha demostrado la capacidad de inhibir de forma directa la funci\u00f3n de la prote\u00edna cMyc, desencadenando una respuesta antitumoral en varios modelos animales. Estamos particularmente interesados \u200b\u200ben la exploraci\u00f3n de enfermedades hematol\u00f3gicas, incluido el mieloma m\u00faltiple, dado que dependen en gran medida de cMyc y brindan la oportunidad de medir r\u00e1pidamente el efecto sobre la diana terap\u00e9utica. En \u00faltima instancia, esperamos ver una respuesta biol\u00f3gica y cl\u00ednica que confirme el amplio potencial de este innovador enfoque terap\u00e9utico en tumores s\u00f3lidos y l\u00edquidos\u201d, explica la <strong>Dra. Laura Nevola<\/strong>, directora cient\u00edfica de IDP Pharma.<\/p>\n<p>Seg\u00fan <strong>Valent\u00edn Caba\u00f1as<\/strong>, investigador principal del <a href=\"https:\/\/www.murciasalud.es\/seccion.php?idsec=347\" target=\"_blank\" rel=\"noopener\">Hospital Cl\u00ednico Universitario Virgen de la Arrixaca<\/a> (Murcia, Espa\u00f1a), donde se administr\u00f3 el IDP-121 al primer paciente, el uso del compuesto para el tratamiento del mieloma m\u00faltiple \u201cpodr\u00eda representar potencialmente un cambio importante en el manejo de la enfermedad debido a la explotaci\u00f3n de un mecanismo de acci\u00f3n previamente inaccesible para atacar a las c\u00e9lulas del mieloma\u201d. El ensayo cl\u00ednico incluir\u00e1 tambi\u00e9n pacientes con linfoma no Hodgkin y leucemia linfoc\u00edtica cr\u00f3nica, ya que este nuevo f\u00e1rmaco \u201cact\u00faa sobre la prote\u00edna implicada en el desarrollo de varios c\u00e1nceres hematol\u00f3gicos m\u00e1s all\u00e1 del mieloma m\u00faltiple\u201d.<\/p>\n<p>\u201cEste es un paso extremadamente importante en la comprensi\u00f3n y relevancia del papel de cMyc en el desarrollo y la progresi\u00f3n del c\u00e1ncer. La capacidad de abordar directamente a la prote\u00edna cMyc en la cl\u00ednica es muy relevante y, por ello, la exploraci\u00f3n de IDP-121 en este estudio cl\u00ednico podr\u00eda marcar un hito en el desarrollo de f\u00e1rmacos oncol\u00f3gicos\u201d, afirma el profesor <a href=\"https:\/\/profiles.stanford.edu\/dean-felsher\">Dean Felsher<\/a>, asesor cient\u00edfico de IDP Pharma y profesor de la \u00a0<a href=\"https:\/\/oncology.stanford.edu\/\" target=\"_blank\" rel=\"noopener\">Divisi\u00f3n de Oncologia<\/a> dentro de los Departamentos de Medicina y Patolog\u00eda de la Universidad de Stanford.<\/p>\n<p>\u00abIDP-121 es el f\u00e1rmaco principal de IDP Pharma y el anuncio de hoy representa un paso adelante hacia la buscada modulaci\u00f3n sistem\u00e1tica y directa de las prote\u00ednas IDP, factores clave en el inicio y desarrollo del c\u00e1ncer hasta la fecha inabordables\u00bb, subtraya <strong>Santiago Esteban<\/strong>, director ejecutivo de IDP Pharma.<\/p>\n<p>El estudio evaluar\u00e1 la seguridad, tolerabilidad, farmacocin\u00e9tica, farmacodinamia y actividad cl\u00ednica preliminar de IDP-121. El investigador principal es el profesor <strong>Enrique Ocio<\/strong>, jefe de Hematolog\u00eda del Hospital Universitario Marqu\u00e9s de Valdecilla, y el estudio incluye otros cuatro centros m\u00e9dicos en Espa\u00f1a: Hospital Universitario Vall d&#8217;Hebron, Hospital Universitario 12 de Octubre, Hospital Cl\u00ednico Universitario de Salamanca y Hospital Universitario Virgen de la Arrixaca.<\/p>\n<p><strong>\u00bb M\u00e1s informaci\u00f3n sobre el ensayo cl\u00ednico IDP-121: <a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05908409\">ClinicalTrials.gov<\/a><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05908409\">|<\/a><a href=\"https:\/\/clinicaltrials.gov\/study\/NCT05908409\">NCT05908409<\/a><\/strong><\/p>\n<p><strong>\u00bb\u00a0<a href=\"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-inicia-el-ensayo-clinico-de-su-farmaco-idp-121-en-tumores-hematologicos-y-abre-una-ronda-de-1-me-para-la-primera-fase-del-estudio\/\" target=\"_blank\" rel=\"noopener\">Noticia relacionada [+]<\/a><\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"<p>IDP Pharma, una empresa de biotecnolog\u00eda en fase cl\u00ednica pionera en el desarrollo de f\u00e1rmacos que bloquean y degradan directamente a las prote\u00ednas intr\u00ednsecamente desordenadas (IDPs, del ingl\u00e9s intrinsically disordered&#8230;<\/p>\n","protected":false},"author":14,"featured_media":89320,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"inline_featured_image":false,"footnotes":""},"categories":[356],"tags":[],"class_list":["post-89328","post","type-post","status-publish","format-standard","has-post-thumbnail","category-empresas"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.7 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2 - Parc Cient\u00edfic de Barcelona<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/\" \/>\n<meta property=\"og:locale\" content=\"es_ES\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2 - Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"og:description\" content=\"IDP Pharma, una empresa de biotecnolog\u00eda en fase cl\u00ednica pionera en el desarrollo de f\u00e1rmacos que bloquean y degradan directamente a las prote\u00ednas intr\u00ednsecamente desordenadas (IDPs, del ingl\u00e9s intrinsically disordered...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Parc Cient\u00edfic de Barcelona\" \/>\n<meta property=\"article:published_time\" content=\"2023-10-26T10:05:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-10-13T13:24:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/IDP-Pharma-1.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1026\" \/>\n\t<meta property=\"og:image:height\" content=\"376\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Paula Ca\u00f1al\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Escrito por\" \/>\n\t<meta name=\"twitter:data1\" content=\"Paula Ca\u00f1al\" \/>\n\t<meta name=\"twitter:label2\" content=\"Tiempo de lectura\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutos\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/\"},\"author\":{\"name\":\"Paula Ca\u00f1al\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"headline\":\"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\\\/2\",\"datePublished\":\"2023-10-26T10:05:57+00:00\",\"dateModified\":\"2025-10-13T13:24:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/\"},\"wordCount\":641,\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/IDP-Pharma-1.jpg\",\"articleSection\":[\"EMPRESAS\"],\"inLanguage\":\"es\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/\",\"name\":\"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\\\/2 - Parc Cient\u00edfic de Barcelona\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/IDP-Pharma-1.jpg\",\"datePublished\":\"2023-10-26T10:05:57+00:00\",\"dateModified\":\"2025-10-13T13:24:44+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/#breadcrumb\"},\"inLanguage\":\"es\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/IDP-Pharma-1.jpg\",\"contentUrl\":\"https:\\\/\\\/www.pcb.ub.edu\\\/wp-content\\\/uploads\\\/2023\\\/10\\\/IDP-Pharma-1.jpg\",\"width\":1026,\"height\":376},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\\\/2\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#website\",\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/\",\"name\":\"Parc Cient\u00edfic de Barcelona\",\"description\":\"Universitat de Barcelona\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"es\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/#\\\/schema\\\/person\\\/dece7d71551633ff3423502f3e384c6a\",\"name\":\"Paula Ca\u00f1al\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"es\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g\",\"caption\":\"Paula Ca\u00f1al\"},\"url\":\"https:\\\/\\\/www.pcb.ub.edu\\\/es\\\/author\\\/paula\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2 - Parc Cient\u00edfic de Barcelona","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/","og_locale":"es_ES","og_type":"article","og_title":"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2 - Parc Cient\u00edfic de Barcelona","og_description":"IDP Pharma, una empresa de biotecnolog\u00eda en fase cl\u00ednica pionera en el desarrollo de f\u00e1rmacos que bloquean y degradan directamente a las prote\u00ednas intr\u00ednsecamente desordenadas (IDPs, del ingl\u00e9s intrinsically disordered...","og_url":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/","og_site_name":"Parc Cient\u00edfic de Barcelona","article_published_time":"2023-10-26T10:05:57+00:00","article_modified_time":"2025-10-13T13:24:44+00:00","og_image":[{"width":1026,"height":376,"url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/IDP-Pharma-1.jpg","type":"image\/jpeg"}],"author":"Paula Ca\u00f1al","twitter_card":"summary_large_image","twitter_misc":{"Escrito por":"Paula Ca\u00f1al","Tiempo de lectura":"3 minutos"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/#article","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/"},"author":{"name":"Paula Ca\u00f1al","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"headline":"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2","datePublished":"2023-10-26T10:05:57+00:00","dateModified":"2025-10-13T13:24:44+00:00","mainEntityOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/"},"wordCount":641,"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/IDP-Pharma-1.jpg","articleSection":["EMPRESAS"],"inLanguage":"es"},{"@type":"WebPage","@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/","url":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/","name":"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2 - Parc Cient\u00edfic de Barcelona","isPartOf":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/#primaryimage"},"image":{"@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/IDP-Pharma-1.jpg","datePublished":"2023-10-26T10:05:57+00:00","dateModified":"2025-10-13T13:24:44+00:00","author":{"@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a"},"breadcrumb":{"@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/#breadcrumb"},"inLanguage":"es","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/"]}]},{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/#primaryimage","url":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/IDP-Pharma-1.jpg","contentUrl":"https:\/\/www.pcb.ub.edu\/wp-content\/uploads\/2023\/10\/IDP-Pharma-1.jpg","width":1026,"height":376},{"@type":"BreadcrumbList","@id":"https:\/\/www.pcb.ub.edu\/es\/idp-pharma-administra-el-farmac-oncologico-idp-121-al-primer-pacient-en-un-assaig-fase-1-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.pcb.ub.edu\/es\/"},{"@type":"ListItem","position":2,"name":"IDP Pharma administra el f\u00e1rmaco oncol\u00f3gico IDP-121 al primer paciente en un ensayo Fase 1\/2"}]},{"@type":"WebSite","@id":"https:\/\/www.pcb.ub.edu\/es\/#website","url":"https:\/\/www.pcb.ub.edu\/es\/","name":"Parc Cient\u00edfic de Barcelona","description":"Universitat de Barcelona","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.pcb.ub.edu\/es\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"es"},{"@type":"Person","@id":"https:\/\/www.pcb.ub.edu\/es\/#\/schema\/person\/dece7d71551633ff3423502f3e384c6a","name":"Paula Ca\u00f1al","image":{"@type":"ImageObject","inLanguage":"es","@id":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/b994665ec600f20526048e5d98eab6b8aa5e116b6fe2101daebcb986872bd355?s=96&d=mm&r=g","caption":"Paula Ca\u00f1al"},"url":"https:\/\/www.pcb.ub.edu\/es\/author\/paula\/"}]}},"_links":{"self":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/89328","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/users\/14"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/comments?post=89328"}],"version-history":[{"count":2,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/89328\/revisions"}],"predecessor-version":[{"id":89343,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/posts\/89328\/revisions\/89343"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media\/89320"}],"wp:attachment":[{"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/media?parent=89328"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/categories?post=89328"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pcb.ub.edu\/es\/wp-json\/wp\/v2\/tags?post=89328"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}